Option chain shows key data for Edesa Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Edesa Biotech.

Edesa Biotech (NASDAQ:EDSA) Stock, Option Chain

Edesa Biotech

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALAR

ATSG

CSWC

EDSA

EFSH

NLSP

NSSC

NUWE

OKLO

OMIC

SIFY

STAF

TGTX

VSTE

YUMC

Why Yum China Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

AAMC

ATNF

BURU

CCCC

CISO

INAB

IOAC

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

MYNA

NXTP

PTPI

RSLS

SFWL

VSME

WLGS

ZJYL

Shares of  ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX.

ReShape Lifesciences shares jumped 44.6% to $0.3630 in pre-market trading.

Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Intraday Update

ADSK

AGIL

ANGH

ATGL

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATPC

CNTB

GHRS

GNTA

GSX Techedu Inc. American Depositary Shares

GOTU

GYRE

HSCS

MIRA

PXMD

RVYL

SHOT

SPRC

TCON

THAR

URBN

Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results.

Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Edesa Biotech Inc

SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares closed Thursday up more than 60%, and the stock isn&#8217;t slowing down after hours. Shares are up more than 3% in extended trading after the company announced it regained compliance with <a href="https://www.benzinga.com/pressreleases/24/12/g42694574/sealsq-regains-compliance-with-nasdaqs-minimum-bid-price-requirement">Nasdaq listing rules</a>.
What Happened: After the market close on Thursday, SEALSQ said it received formal written notice from the Nasdaq confirming that the company regained compliance with the Nasdaq&#8217;s minimum bid price requirement.
SEALSQ received a letter from the Nasdaq on Aug. 1, stating that the company was not in compliance with the&nbsp;$1&nbsp;minimum bid price requirement for continued listing on the Nasdaq. The company was required to maintain a minimum bid price of at least $1 for 10 consecutive trading days prior to Jan. 28. 
SEALSQ said it was informed that it regained compliance after its shares traded above the $1 level from Dec. 11 to Dec. 24. Shares are responding favorably to the announcement that the matter is now closed. SEALSQ shares are now up more than 2,000% over the past month, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
SEALSQ stock rallied more than 60% during normal trading hours on Thursday after the company announced the launch of SEALQUANTUM.com Lab, designed to support organizations transitioning to&nbsp;quantum-safe encryption. 
&#8220;As quantum technologies become a reality, the need for quantum-safe encryption solutions grows increasingly urgent,&#8221; said Carlos Moreira, CEO of SEALSQ. 
&#8220;Our&nbsp;SEALQUANTUM.com&nbsp;Lab is more than just a platform, it&#8217;s a commitment to future-proofing our clients&#8217; security. By combining cutting-edge research with actionable tools, we&#8217;re empowering businesses to navigate the complexities of quantum cryptography with confidence.&#8221;
SEALSQ describes itself as &#8220;a company that focuses on developing and selling semiconductors, PKI and post-quantum technology hardware and software products.&#8221;
Check This Out: <a href="https://www.benzinga.com/24/12/42686387/sealsq-launches-sealquantumcom-lab-to-help-businesses-transition-to-quantum-safe-encryption">SEALSQ Launches SEALQUANTUM.com Lab To Help Businesses Transition To Quantum-Safe Encryption</a>
LAES Price Action: <a href="http://benzinga.com/quote/laes">SEALSQ shares</a> were up 0.23% in after hours, trading at $8.78 at the time of publication Thursday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Tech

LAES

SEALSQ Corp Shares Are Moving Higher After Hours: What's Going On?

Editor&#8217;s note: This story has been updated with comment from Zelle and Bank of America. 
The Consumer Financial Protection Bureau sued three of the nation's largest banks and the operator of Zelle last week, alleging a failure to protect consumers from widespread fraud on the peer-to-peer payment network, resulting in customer losses of more than <a href="https://www.benzinga.com/markets/equities/24/08/40155365/zelle-controversy-heats-up-jpmorgan-considers-legal-action">$870 million since 2017.&nbsp;</a>
The Details: The CFPB's <a href="https://www.consumerfinance.gov/enforcement/actions/early-warning-services-llc-bank-of-america-na-jpmorgan-chase-bank-na-wells-fargo-bank-na/">lawsuit</a> alleges that JP Morgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) and Early Warning Services rushed to complete the Zelle payment network in order to compete with Venmo and CashApp and neglected to enact effective fraud safeguards. 
Read Next: <a href="https://www.benzinga.com/news/24/12/42669113/waymos-autonomous-vehicles-are-safer-than-human-drivers-report">Waymo&#8217;s Autonomous Vehicles Are Safer Than Human Drivers: Report</a>
"The nation's largest banks felt threatened by competing payment apps, so they rushed to put out Zelle," said CFPB Director Rohit Chopra. "By their failing to put in place proper safeguards, Zelle became a gold mine for fraudsters, while often leaving victims to fend for themselves."
The lawsuit further alleges that the banks "systemically failed" their customers by failing to properly investigate customer complaints or share information on known acts of fraud which allowed bad actors to hop between banks and commit repeated fraudulent transactions.&nbsp;
Zelle told Benzinga in an emailed statement that it sees the CFPB's lawsuit as politically motivated and&nbsp; "legally and factually flawed." Zelle said it "leads the fight against scams and fraud" and that its reimbursement policies exceed those required by law.
"The CFPB's misguided attacks will embolden criminals, cost consumers more in fees, stifle small businesses and make it harder for thousands of community banks and credit unions to compete,&#8221; said&nbsp;Jane Khodos, Zelle spokesperson.
A Bank of America spokesperson told Benzinga that more than 99.5% of Zelle transactions go through without incident and when an issue arises, the bank works directly with the customer to resolve it.
"We strongly disagree with the CFPB's effort to impose huge new costs on the 2,200 banks and credit unions that offer the free Zelle service to clients," Bank of America added.
Benzinga also contacted JPMorgan, Wells Fargo, Bank of America and Early Warning Services for comment on the lawsuit.
JPMorgan told CBS News that the CFPB has a &#8220;political agenda,&#8221;and the agency is &#8220;overreaching its authority by making banks accountable for criminals, even including romance scammers.&#8221;
The CFPB said its lawsuit aims to stop the banks' alleged unlawful practices, secure penalties for the violations and obtain other relief for consumers.&nbsp;
"The banks failed to fix glaring flaws in their systems even as hundreds of thousands of customers filed complaints about fraud," Chopra said in a <a href="https://www.consumerfinance.gov/about-us/newsroom/prepared-press-call-remarks-of-cfpb-director-rohit-chopra-on-the-zelle-lawsuit-announcement/">statement</a>.
"The banks knew their customers were having their money stolen, but since they weren't bearing the cost of these losses themselves, they dragged their feet on fixing the problems," he added.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42653466/honda-nissan-plan-to-merge-in-the-face-of-chinese-ev-competition">Honda, Nissan Confirm Merger Plans To Offset Chinese EV Competition: How Mitsubishi Factors In</a></li>
</ul>
Image: Shutterstock.

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Legal

'Zelle Became A Gold Mine For Fraudsters': Consumer Financial Protection Bureau Lawsuit (UPDATED)

The company announced that following the results of the Company's 2024 Annual Meeting, three new directors were elected to the Board of Directors by its stockholders: John A. Moore, General Victor E. Renuart Jr. and Robert D. Straus.

Management

TPCS

TechPrecision Board Appoints Victor Renuart To Serve As Chair And Robert Straus As Vice-chair

Guidance

CRKN

Crown Electrokinetics CEO Highlights 2024 Achievements And 2025 Goals; Reports $20M Revenue For 2024, Projects Profitability By H1 2025; Appeals NASDAQ Delisting With Reverse Stock Split Proposal Ahead Of Jan. 14 Vote

The company emphasized that its decision to voluntarily close the trial is not the result of any new safety finding.

VIRX

Viracta Therapeutics Plans To Close Its Ongoing Pivotal Phase 2 Clinical Trial Of Nana-val In Relapsed/Refractory EBV + Lymphomas

Viracta Therapeutics Board Initiates Process To Explore Broad Range Of Strategic Alternatives

PLBY

PLBY Group Enters Retention Agreement With Each Of Its Named Executive Officers: Ben Kohn, CEO And President; Marc Crossman, CFO And COO; And Chris Riley, General Counsel And Secretary - Filing

Federally funded&nbsp;survey data&nbsp;provided by the University of Michigan indicates&nbsp;that teen marijuana use has declined significantly over the past decade and is now at historic lows.
Consistent with data previously reported by the <a href="https://norml.org/blog/2024/08/07/cdc-data-highlights-sustained-decline-in-youth-marijuana-use/">Centers for Disease Control and Prevention</a> and the <a href="https://norml.org/blog/2024/07/31/government-survey-data-shows-nearly-20-percent-decline-in-teen-marijuana-use-over-past-decade/">National Survey on Drug Use and Health</a>, the University of Michigan's annual Monitoring the Future report finds that cannabis use by young people is at a 30-year low. The federally funded Monitoring the Future survey has been operating since 1975.
This year's&nbsp;<a href="https://monitoringthefuture.org/data/index.html" target="_blank" rel="noreferrer noopener">findings</a> are based on responses from about 24,000 students in grades 8, 10 and 12 in schools across the U.S. The survey is "one of the best, if not the best" source of national data for substance use by teens, said Noah Kreski, a Columbia University researcher who has studied teen drug use, <a href="https://apnews.com/article/teen-drug-use-b5e877b4c7eecb5354c3b8214e7d8692">noted</a> the AP.
In a Dec. 17 <a href="https://nida.nih.gov/news-events/news-releases/2024/12/reported-use-of-most-drugs-among-adolescents-remained-low-in-2024">press release</a> issued by the National Institutes of Health on the same day of the report, <a href="https://www.benzinga.com/topic/nora-volkow">Nora Volkow</a>, M.D., director of NIH's National Institute on Drug Abuse described the overall decline in substance use by young people as "unprecedented."
Read Also: <a href="https://www.benzinga.com/24/12/42690082/trump-is-first-republican-president-with-a-pathway-to-cannabis-reform-says-former-adviser">Trump Is First &#8216;Republican President&#8217; With A Pathway To Cannabis Reform, Says Former Adviser</a>
"This trend in the reduction of substance use among teenagers is unprecedented," Volkow said. "We must continue to investigate factors that have contributed to this lowered risk of substance use to tailor interventions to support the continuation of this trend."&nbsp;
Over the past 10 years, during which time 24 states legalized adult-use marijuana sales, the percentage of 8th graders, 10th graders and 12 graders who reported having ever consumed cannabis declined 32%, 37% and 23%, respectively, according to the study.
"Sensational claims that adult-use legalization laws are linked with greater marijuana use by teens are simply not backed by reliable data," said <a href="https://www.benzinga.com/topic/paul-armentano">Paul Armentano</a>, deputy director  of the National Organization for the Reform of Marijuana Laws. "These findings ought to reassure lawmakers that cannabis access can be legally regulated in a manner that is safe, effective, and that does not inadvertently impact young people's habits."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/12/42597912/pesticides-in-pot-the-overlooked-dangers-of-californias-legal-weed">Pesticides In Pot: Overlooked Dangers Of California&#8217;s Legal Weed</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Cannabis

Government

Cannabis Use Among Teens Plummets To 30-Year Low, Study Finds

The company announced the sale of a portion of its available-for-sale investment securities portfolio as part of a strategic balance sheet repositioning.
Additionally, the Bank maintains liquidity metrics, including holding over $35 million in cash, cash equivalents, and Treasury securities. Additionally, the Bank has an unused secured line of credit of over $250 million with the Federal Home Loan Bank of New York.
&nbsp;

RBKB

Rhinebeck Bancorp Says Remained 'Well Capitalized' Following Restructuring; Says Restructuring Decreased Average Life Of The Securities Portfolio And Is Expected To Improve Earnings Stream Beginning In Q1'25

IMKTA

Ingles Markets Announced That It Received A Notice From Nasdaq Stating The Company Is No Longer In Compliance With Nasdaq Listing Rule 5250(c)

Bank Of America Reveals Full Redemption Of Its Series MM Preferred Stock And Related Depositary Shares

WIIM

AREN

The Arena Group Holdings shares are trading higher after the company's compliance plan was accepted by the NYSE American.

Offerings

Orange County Bancorp Announced A Two-For-One Forward Stock Split

OMEX

Odyssey Marine Exploration shares are trading higher following the purchase of 250,000 shares by a company director.

Foot traffic at retailers soared on Dec. 21, the Saturday before Christmas. Here's a look at the potential winners from the last week <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42273676/walmart-target-bath-body-works-stand-out-as-black-friday-winners-analysts">of holiday shopping.</a>
What Happened: Foot traffic at retailers was up an average of 58% compared to daily averages in 2024, a trend that could see retail stocks benefit for the 2024 <a href="https://www.benzinga.com/news/24/11/42247997/walmart-shoppers-shun-electronics-for-black-friday-deals-on-eggs-bread-slippers">holiday shopping season.</a>
The 58% gain to the daily average, <a href="https://www.placer.ai/blog/super-saturday-2024-recap">reported </a>by Placer.ai, is higher than the 51.1% gain over the daily average seen on Black Friday. Sunday, Dec. 22, also saw retail foot traffic up 38.2% to the daily average.
While foot traffic was up compared to the daily average for the year, the 58% gain was smaller than last year's Super Saturday, which saw a 74.4% increase from the daily average. The caveat with last year's data is that Super Saturday was Dec. 23, one of the last remaining shopping days before Christmas.
Among the potential biggest winners for this year's Christmas shopping season could be department stores, based on the report.
Overall foot traffic to department stores was up 128.7% compared to the Saturday 2024 daily average, surpassing last year&#8217;s 119.4% increase over the 2023 Saturday average.
Among the department stores tracked by Placer.ai, these were the year-over-year visit growth:
<ul>
<li>Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>): +8.8%</li>
<li>Bloomingdale's, a unit of Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>): +4.7%</li>
<li>JCPenney: +1.3%</li>
</ul>
The report also found that recreational and sporting goods stores, beauty and self-care stores and other specialty categories saw strong traffic gains. Here's a look at some of the retailers tracked and the foot traffic gains on a year-over-year basis to last year's Super Saturday:
<ul>
<li>Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>): +7.3%</li>
<li>T.J. Maxx, a unit of TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>): +4.6%</li>
<li>Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>): +4.2%</li>
</ul>
The report found that superstores, grocery stores, and discount retailers saw lower year-over-year growth due to last year's timing of Super Saturday being so close to Christmas.
Indoor shopping malls like those owned by Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) may have also benefitted from Super Saturday. Placer.ai data shows that foot traffic to indoor malls was up 177.1% on Super Saturday compared to the 2024 daily average.
Read Also: <a href="https://www.benzinga.com/general/education/24/12/42678116/if-you-gifted-your-family-100-in-bitcoin-dogecoin-and-ethereum-last-christmas-heres-how-much-they-would-have-this-christmas-2">If You Gifted Your Family $100 In Bitcoin, Dogecoin And Ethereum Last Christmas, Here&#8217;s How Much They Would Have This Christmas</a>
Why It's Important: Ahead of Super Saturday, the National Retail Foundation <a href="https://nrf.com/media-center/press-releases/157-million-consumers-to-shop-on-super-saturday">estimated </a>that 157.2 million consumers would shop on the shopping holiday based on an annual survey.
The figure comes in higher than the 141.9 million Super Saturday shoppers in 2024 and is the second highest figure over the last nine years, trailing only 158.5 million in 2022.
"Super Saturday is one of the last opportunities during the holiday season for consumers to get the remaining items on their shopping list," NRF Vice President of Industry and Consumer Insights Katherine Cullen said.
Cullen cited the shortened holiday shopping season, due to Thanksgiving falling late in November, boosting the odds of last-minute shoppers.
The survey found that 69.5 million people plan to shop both in-store and online, up from 58.3 million in 2023. The amount of people exclusively shopping in-store was down in the survey from 37% to 31%, while the percentage of people who said they would shop exclusively online increased from 22% to 24%.
Similar to the results above, the NRF survey highlighted department stores as potential winners on Super Saturday, with 37% of shoppers saying they planned to finish their holiday shopping there.
Finishing shopping online was the most popular response at 49%, with discount stores named by 27% of consumers and clothing and accessory stores named by 25% of consumers.
The NRF survey found the most popular gift purchases were clothing and accessories (50%), toys (32%), gift cards (26%) and books, video games and other media (24%).
The shortened holiday shopping season could have been good for retailers with more foot traffic each day and especially on the weekends. The key will be if the daily increase is enough to offset the lower number of total shopping days between Thanksgiving and Christmas.
The post-Christmas shopping time could also see a boost, with 71% of consumers in the survey saying they planned to shop after Christmas, similar to last year's survey.
NRF estimates that the entire holiday shopping season of Nov. 1 through Dec. 31 is expected to be up 2.5% to 3% from 2024, hitting a record range of $979.5 billion to $989 billion.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/12/42658677/better-christmas-gift-gamestop-stock-or-latest-video-game">Better Christmas Gift: GameStop Stock Or Latest Video Game?</a></li>
</ul>
Photo: Shutterstock

FIVE

OLLI

Super Saturday Foot Traffic Surges, Sales Hit $157 Million: Potential Winners Emerge

Insider Trades

Odyssey Marine Exploration Director Mark B Justh Discloses Purchase Of 250,000 Shares

The Arena Group Plan To Regain NYSE Compliance Accepted

SEALSQ Receives Formal Written Confirmation From Nasdaq Confirming That It Has Regained Compliance With Minimum Bid Price Requirement

<h3>Gainers</h3>
<ul>
<li>Kore Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) stock increased by 14.9% to $2.16 during Thursday's pre-market session. The market value of their outstanding shares is at $36.7 million. </li>
<li>Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) stock rose 10.89% to $2.95. The company's market cap stands at $41.7 million. </li>
<li>Gaxos.AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) shares moved upwards by 9.8% to $2.8. The company's market cap stands at $10.3 million. </li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) shares rose 8.36% to $0.48. The company's market cap stands at $4.2 million. </li>
<li>Shenandoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHEN#NASDAQ">SHEN</a>) stock rose 7.47% to $13.8. The company's market cap stands at $753.5 million. </li>
<li>FingerMotion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNGR#NASDAQ">FNGR</a>) shares rose 7.27% to $1.18. The company's market cap stands at $67.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) shares decreased by 26.1% to $5.25 during Thursday's pre-market session. The company's market cap stands at $8.0 million. </li>
<li>Brera Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BREA#NASDAQ">BREA</a>) stock decreased by 20.0% to $0.8. The market value of their outstanding shares is at $10.6 million. </li>
<li>Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) stock fell 16.72% to $3.09. The company's market cap stands at $46.6 million. </li>
<li>Treasure Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) stock fell 8.18% to $0.21. The market value of their outstanding shares is at $2.2 million. </li>
<li>Onfolio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) stock decreased by 6.67% to $1.26. The company's market cap stands at $6.4 million. </li>
<li>VS Media Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) stock fell 6.62% to $1.13. The market value of their outstanding shares is at $3.6 million. The company's, H1 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASST

BAOS

BREA

DRCT

FNGR

GXAI

KORE

ONFO

SHEN

ZDGE

12 Communication Services Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares rose 118.1% to $0.31 during Thursday's pre-market session. The market value of their outstanding shares is at $12.7 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock moved upwards by 24.67% to $1.21. The market value of their outstanding shares is at $17.5 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares rose 23.07% to $0.48. The company's market cap stands at $1.9 million. </li>
<li>TScan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) stock rose 15.46% to $3.36. The market value of their outstanding shares is at $179.3 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) stock increased by 12.71% to $1.95. The market value of their outstanding shares is at $68.1 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock rose 12.64% to $0.34. The company's market cap stands at $2.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) stock fell 23.5% to $1.24 during Thursday's pre-market session. The market value of their outstanding shares is at $50.9 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock declined by 18.23% to $0.3. The company's market cap stands at $2.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 16.56% to $2.42. The company's market cap stands at $4.7 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock decreased by 15.71% to $0.24. The company's market cap stands at $5.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares fell 14.78% to $1.5. The company's market cap stands at $4.1 million. </li>
<li>NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) stock decreased by 10.6% to $9.96. The company's market cap stands at $297.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

ANEB

COEP

CTCX

NPCE

RAPT

REVB

SXTC

TCRX

TIVC

TOVX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Edesa Biotech (EDSA) has released an update. Edesa Biotech's novel drug, paridiprubart, has been selected by the U.S. Biomedical Advanced Research ...

Edesa Biotech's ARDS Drug Chosen for US Trial

Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Edesa Biotech (EDSA – Research Report). The associated price targe...

Promising Outlook for Edesa Biotech's Paridiprubart: A Buy Rating Justified by BARDA-Backed ARDS Study and Broad Therapeutic Potential

Edesa Biotech GAAP EPS of -$0.52 beats by $0.06

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its third-quarter financials ...

Edesa Biotech Showcases Steady Q3 2024 Financials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Edesa Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/edsa-stock-quote/">EDSA</a>) just reported results for the third quarter of 2024.<ul><li>Edesa Biotech reported earnings per share of -52 cents. This was above the analyst estimate for EPS of -58 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/edsa-stock-earnings-edesa-biotech-for-q3-of-2024/">EDSA Stock Earnings: Edesa Biotech Beats EPS for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EDSA Stock Earnings: Edesa Biotech Beats EPS for Q3 2024

Buy Rating Affirmed for Edesa Biotech Amidst Strong Government Support and Promising Drug Pipeline

Edesa Biotech ( ($EDSA) ) has issued an update. Edesa Biotech, Inc. has partnered with H.C. Wainwright & Co., LLC to periodically sell its common s...

Edesa Biotech Partners with Wainwright for Share Sales

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, is set to participate in multiple internati...

Edesa Biotech to Present at Global Conferences

Edesa Biotech GAAP EPS of -$1.93 beats by $0.22

Edesa Biotech (EDSA) has released an update. Edesa Biotech reported a significant decrease in operating expenses for fiscal year 2024, with a pivot...

Edesa Biotech Enhances Financial Position and Strategy

Biotech

Events

Press Releases

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Edesa Biotech to Participate in Upcoming Investor Conferences

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Earnings

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Comments

Edesa Biotech

Edesa Biotech (EDSA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga